Published in

American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 6(65), 2021

DOI: 10.1128/aac.00124-21

Links

Tools

Export citation

Search in Google Scholar

Emergence of Resistance to Ceftazidime-Avibactam in a Pseudomonas aeruginosa Isolate Producing Derepressed bla <sub>PDC</sub> in a Hollow-Fiber Infection Model

Journal article published in 2021 by G. L. Drusano ORCID, Robert A. Bonomo ORCID, Steven M. Marshall, Laura J. Rojas, Mark D. Adams ORCID, Maria F. Mojica, Barry N. Kreiswirth, Liang Chen ORCID, Nino Mtchedlidze, Meredith Bacci, Michael Vicchiarelli, Jürgen B. Bulitta ORCID, Arnold Louie
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Orange circle
Published version: archiving restricted
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Ceftazidime (CAZ)-avibactam (AVI) is a β-lactam/β-lactamase inhibitor combination with activity against type A and type C β-lactamases. Resistance emergence has been seen, with multiple mechanisms accounting for the resistance. We performed four experiments in the dynamic hollow-fiber infection model, delineating the linkage between drug exposure and both the rate of bacterial kill and resistance emergence by all mechanisms.